TOPNews Release

News Release

2014

31/7/2014
Taiho Pharmaceutical Announces Termination of Phase III Clinical Trial of the Angiogenesis Inhibitor TSU-68 (orantinib) in Patients with Hepatocellular Carcinoma
25/7/2014
Phase III Clinical Study of S-1 in Patients with Advanced Hepatocellular Carcinoma Did Not Meet Its Primary Endpoint
23/7/2014
Taiho Pharmaceutical Invests US$ 30 Million in Remiges BioPharma Fund, LP to Foster Early Biotech Start-ups
2/7/2014
Application for the Additional Indication of Febrile Neutropenia for ZOSYN®, an Injectable Antibiotic Combined with β-Lactamase Inhibitor
30/6/2014
Taiho Pharmaceutical Announces Results from TAS-102 Global Phase III RECOURSE Trial in Refractory Metastatic Colorectal Cancer
11/6/2014
Taiho Pharmaceutical Announces Personnel Changes (PDF:132KB)
4/6/2014
Data from Phase II Trial of ET-743 (trabectedin), a Novel Antitumor Agent, in Patients with Malignant Soft Tissue Sarcoma Presented at ASCO®
3/6/2014
Results of Phase III Clinical Study (SELECT BC) of TS-1 Treatment for Metastatic Breast Cancer Announced at ASCO®
23/5/2014
Anticancer Drug Lonsurf® Combination Tablet Receives NHI Reimbursement Price Listing and is Scheduled for Launch
12/5/2014
Taiho Oncology's TAS-102 Meets Primary Endpoint of Improving Overall Survival in Global Phase III RECOURSE Trial in Refractory Metastatic Colorectal Cancer
22/4/2014
ET-743 (trabectedin), a Novel Antitumor Agent Meets Primary Endpoint of Progression Free Survival Prolongation in a Phase 2 Trial in Malignant Soft Tissue Sarcoma Patients
24/3/2014
Taiho's Lonsurf® (trifluridine and tipiracil hydrochloride) Tablets Approved in Japan for Treatment in Advanced Metastatic Colorectal Cancer
6/1/2014
Transfer of Astellas' Fermentation Research-Related Assets to Taiho Pharmaceutical (PDF:153KB)

Top of Page

2013

Top of Page

2012

30/11/2012
Announcement; Launch of 5-HT3 Receptor Antagonist Aloxi® I.V. infusion bag 0.75mg
28/9/2012
ZOSYN®, an Injectable Antibiotic Combination Product Receives an Approval for Peritonitis,
Intra-abdominal Abscess, Cholecystitis, and Cholangitis
18/9/2012
Clinical Trial (JASPAC01) of TS-1 for Resected Pancreatic Cancer
28/8/2012
Results of a Phase II Clinical Trial for the Novel Antitumor Agent TAS-102 Posted on the Electronic Edition of The Lancet Oncology
24/7/2012
Taiho and Faes Farma (Spain) Enter into a License Agreement on Anti-Allergy Agent
11/7/2012
Business Partnership regarding Breakthrough Cancer Pain Reliever "OVF" (PDF:59KB)
22/6/2012
Launch of Histamine H2 Receptor Antagonist PROTECADIN® OD Tablets (Orally Disintegrating Tablet)
6/6/2012
Phase III Clinical Trial (CATS TRIAL) for Non-small-cell Lung Cancer Non-inferiority of TS-1 + Cisplatin Treatment Verified Presented to the American Society of Clinical Oncology (ASCO)
31/5/2012
Taiho Pharmaceutical Announces the Start of a Global Phase III Clinical Trial
in Metastatic Colorectal Cancer with the Novel Antitumor Agent TAS-102
16/4/2012
Distributor change for Lentinan I.V. Infusion 1mg "Ajinomoto", an anti-tumor agent (PDF:57KB)
11/4/2012
Anti-Cancer Drug Teysuno® has been launched in the United Kingdom.
11/4/2012
Taiho Pharmaceutical's Anticancer Agent TS-1 Approved for Market in Hong Kong
30/3/2012
Termination of co-development of a β3-adrenoceptor agonist (PDF:61KB)
21/3/2012
Anti-Cancer Drug Teysuno® has been launched in Sweden, Denmark, Norway and Finland
21/3/2012
Taiho Pharmaceutical's Anticancer Agent TS-1 Approved for Market in Thailand
9/3/2012
Licensing Agreement Cancelled for NST-141 Agent for Pruritus in Atopic Dermatitis
1/3/2012
ABRAXANE® I.V. Infusion 100mg Application
Submitted for Approval of Additional Indications in Japan

Top of Page

2011

Top of Page

2010

Top of Page

2009

Top of Page

2008

1/10/2008
Basic agreement reached with Nippon Shinyaku for the collaborative development and marketing of a new antipruritic agent (code NS-141)
1/10/2008
Domestic manufacture of downsized Uzel (calcium folinate) 25 mg tablets to be started soon
1/10/2008
Autumn 2008 version TV commercial for Tiovita Drink is aired
30/9/2008
Zosyn, a new injectable combination antibiotic of beta-lactamase inhibitor and penicillin domestically launched on October 1
30/9/2008
Taiho Pharmaceutical collaborates with and supports the Japan Pink Ribbon Campaign for this year
29/9/2008
46th fiscal-year (07/2007- 06/2008) report is released
22/9/2008
New website contents to promote medical check-ups for breast cancer are released
2/9/2008
The antipsoriatic ethical drugs, Urepearl-Plus Lotion 10 and Urepearl-Plus Cream are launched on September 3
20/8/2008
8th Oncology Media Seminar is held: Main topic - Current therapyfor breast cancer
25/7/2008
Notice: Three Otsuka group companies (Otsuka Pharmaceutical Factory, Otsuka Warehouse, and Taiho Pharmaceutical) are reorganized as wholly-owned direct subsidiaries
18/7/2008
License agreement with Sanofi-Aventis on TS-1 is terminated
18/7/2008
Results of a randomized comparative phase 3 study of S-1 in advanced/recurrent gastric cancer become available
16/7/2008
Notice: Acquisition of production/distribution license for Zosyn, a new injectable combination antibiotic of beta-lactamase inhibitor and penicillin
24/6/2008
Summer 2008 version TV commercial for Tiovita Drink is aired
7/4/2008
7th Oncology Media Seminar is opened: Main topic - Gastric cancer: Clinical studies of oral anti-gastric cancer agents and guidelines for the treatment of gastric cancer
25/3/2008
Results of a randomized comparative study of S-1 monotherapy compared to S-1 with cisplatin (SPIRITS trial) in advanced/recurrent gastric cancer is published in Lancet Oncology: New standard therapy for advanced gastric cancer anticipated
18/1/2008
Spring 2008 version TV commercial for Tiovita Drink is aired
Get ADOBE READER

To view PDF contents, you need the latest version of the Adobe Reader.


Top of Page